Principal investigator Yuan awarded NIH R01 grant
January 22, 2020
Principal investigator Lijuan Yuan, professor of virology and immunology in the Department of Biomedical Sciences and Pathobiology, has been awarded a four-year R01 grant from the National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to address norovirus and Clostridium difficile gastroenteritis by way of engineered probiotic yeast.
Preventing norovirus and Clostridium difficile gastroenteritis by engineered probiotic yeast Saccharomyces boulardii secreting multi-specific single-domain antibodies
NIAID / NIH
Award to Lijuan Yuan: $1,547,822
DURATION OF AWARD
Jan. 22, 2020 — Dec. 31, 2024
KEY FACULTY PERSONNEL
PI: Lijuan Yuan (MPI); Hangping Feng (contact PI), University of Maryland at Baltimore
Co-I: Viviana Parreño, National Agricultural Technology Institute (INTA), Argentina
Human norovirus and Clostridium difficile represent two leading causes of acute gastroenteritis worldwide with significant morbidity and mortality. Despite great efforts in the development of vaccines against both infections, to date there is still no vaccine available on the market. NIAID, NIH awarded a five year R01 to the collaborative team of Dr. Lijuan Yuan at Virginia Tech, Dr. Hangping Feng at University of Maryland at Baltimore, and Dr. Viviana Parreño at INTA, Argentina, to develop a novel prophylaxis using genetically engineered probiotic Saccharomyces boulardii to secrete “Sb-aNoVCd”, multi-specific single-domain VHH antibodies against both noroviruses and Clostridium difficile toxins. The encapsulated Sb-aNoVCd will be used orally for the prevention and treatment of human norovirus and Clostridium difficile gastroenteritis.